中国现代医学杂志2017，Vol.27Issue(10)：103-106,4.DOI:10.3969/j.issn.1005-8982.2017.10.021
吉西他滨联合替吉奥与联合顺铂治疗晚期胰腺癌的疗效比较
Comparison of clinical efficacy of Gemcitabine plus S-1 with Gemcitabine plus Cisplatin in treatment of advanced pancreatic cancer
徐子舒 1吴欣爱1
作者信息
- 1. 郑州大学第一附属医院肿瘤内科,河南郑州450052
- 折叠
摘要
Abstract
Objective To compare the clinical efficacy and safety of Gemcitabine plus S-1 with Gemcitabine plus Cisplatin in the treatment of advanced pancreatic cancer.Methods Forty-five patients with advanced pancreatic cancer were randomly divided into Gemcitabine plus S-1 (GS) group (23 cases) and Gemcitabine plus Cisplatin (GP)group (22 cases).The patients in the GS group were treated with Gemcitabine 1000 mg/m2 intravenous drip on days 1 and 8,and S-1 capsules 75 mg/(m2·d),twice a day on days 1-14,repeated every 21 days.The patients in the GP group received Gemcitabine 1000 mg/m2 intravenous drip on days 1 and 8,and Cisplatin 25 mg/(m2·d) intravenous drip on days 2-4,repeated every 21 days.Results The disease control rate was 78.3％ in the GS group and 72.7％ in the GP group,there was no significant difference (P ＞ 0.05).In the GS group and the GP group,the median progression-free survival (PFS) was 5.75 months and 4.5 months respectively (P ＜ 0.05),and the median overall survival was 9 months and 8 months respectively (P ＞ 0.05).The main adverse reactions were hematology toxicity and gastrointestinal reactions in both groups.The incidences of nausea and vomiting in the GP group were significantly higher than those in the GS group (P ＜ 0.05).Conclusions Both regimens are effective and safe for the treatment of advanced pancreatic cancer.Compared to the GP regimen,GS regimen has lower incidences of adverse reactions and excellent tolerance,it also shows superiority in prolonging survival time though without statistical difference.关键词
胰腺癌/吉西他滨/替吉奥/顺铂Key words
pancreatic cancer/Gemcitabine/S-1/Cisplatin分类
医药卫生引用本文复制引用
徐子舒,吴欣爱..吉西他滨联合替吉奥与联合顺铂治疗晚期胰腺癌的疗效比较[J].中国现代医学杂志,2017,27(10):103-106,4.
